Although developing STING agonists is still the major direction when speaking of targeting the cGAS–STING pathway in cancer treatment, in some patient populations, inhibition of chronic inflammation arising from STING signaling might be a more sensible approach given the role of STING in promoting metastatic progression (Bakhoum et al., 2018). The gene discussed is STING1; the disease is cancer.